

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Guy A. Rouleau *et al.*

Serial No.: 10/664,422

Filed: September 17, 2003

For: LOCI FOR IDOPATHIC GENERALIZED  
EPILEPSY, MUTATIONS THEREOF  
AND METHOD USING SAME TO  
ASSESS, DIAGNOSE, PROGNOSIS OR  
TREAT EPILEPSY

Group Art Unit: 1649

Examiner: Daniel E. Kolker

Atty. Dkt. No.: GOUD:023USD3

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: October 16, 2008

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(e) no item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Supplemental Information Statement. Therefore, No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:023USD3.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek  
Reg. No. 51,898  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: October 16, 2006

Form PTO-1449 (modified)		Atty. Docket No. GOUN:023USD3	Serial No. 10/664,422
List of Patents and Publications for Applicant's		Applicant Guy A. Rouleau <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: September 17, 2003	Group: 1649
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A2	6,110,672	08/29/00	Mandel <i>et al.</i>	435	6	11/02/95

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B2	WO 96/14077	05/17/96	WIPO	English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	NCBI Accession No. X03638.
	C76	Noda <i>et al.</i> , "Existence of distinct sodium channel messenger RNAs in rat brain," <i>Nature</i> , 320: 188-192, 1986.
	C77	Rudinger, "Characteristics of the amino acids as components of a peptide hormone sequence," In: <i>Peptide Hormones</i> (ed. J.A. Parsons) University Park Press, Baltimore, pp. 1-7, 1976.
	C78	Wang <i>et al.</i> , "Pharmacological Targeting of Long QT Mutant Sodium Channels," <i>J. Clin. Invest.</i> , 99:1714-1720, 1997.

25703837.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPEP509; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)